Articles - Malaria

Genomic malaria surveillance of antenatal care users detects reduced transmission following elimination interventions in Mozambique

Genomics reveals heterogeneous Plasmodium falciparum transmission and selection signals in Zambia

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial

 Promising Results for New Malaria Vaccine in African Children A phase 3 clinical trial published in The Lancet provides strong evidence that a new malaria vaccine, R21/Matrix-M, is highly efficacious and safe in African children. The randomized controlled trial was conducted at sites across four sub-Saharan African countries from 2021-2022. Nearly 5000 children aged 5-36 months received three doses of the R21/Matrix-M vaccine or a control rabies vaccine.

Bridging the gap to malaria vaccination in Africa: Challenges and opportunities

Cabo Verde eliminates malaria

Integrating vaccines and monoclonal antibodies into malaria prevention

World Malaria report 2023

Malaria in 2022: Increasing challenges, cautious optimism

Harnessing AI to Predict Malaria Outbreaks: A Game-Changer in Disease Prevention

The art of medicine Artesunate versus quinine: the controlled trials watershed

Epidemiology, Biodiversity, and Technological Trajectories in the Brazilian Amazon: From Malaria to COVID-19

The Amazon biome is under severe threat due to increasing deforestation rates and loss of biodiversity and ecosystem services while sustaining a high burden of neglected tropical diseases. Approximately two thirds of this biome are located within Brazilian territory. There, socio-economic and environmental landscape transformations are linked to the regional agrarian economy dynamics, which has developed into six techno-productive trajectories (TTs).

Cost-effectiveness of intermittent preventive treatment with dihydroartemisinin-piperaquine for malaria during pregnancy: an analysis using efficacy results from Uganda and Kenya, and pooled data

The authors aimed to estimate the cost-effectiveness of intermittent preventive treatment in pregnancy with dihydroartemisinin-piperaquine (IPTp-DP) versus IPTp-SP to prevent clinical malaria infection (and its sequelae) during pregnancy. Findings suggest that among HIV-negative pregnant women with high uptake of long-lasting insecticidal nets, IPTp-DP is cost-effective in areas with high malaria transmission and high sulfadoxine-pyrimethamine resistance. These data provide a comprehensive overview of the current evidence on the cost-effectiveness of IPTp-DP. Nevertheless, before a policy change is advocated, we recommend further research into the effectiveness and costs of different regimens of IPTp-DP in settings with different underlying sulfadoxine-pyrimethamine resistance.